Targeted Oncology

Aglatimagene Besadenovec Shows Durable Survival in ICI-Refractory NSCLC

Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...
Nasdaq

Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in ...

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an investigational immunotherapeutic for solid tumors and subsidiary of Beyond Air ...
Morningstar

Williams Cancer Institute Presents Data on Combined Pulsed Electrical Field Ablation and Intratumoral Immunotherapy at SITC 2025

BEVERLY HILLS, Calif., Nov. 10, 2025 /PRNewswire/ -- Williams Cancer Institute ("WCI"), a leading center pioneering the use of intratumoral immunotherapy for late-stage cancer patients, announced that ...
ascopubs.org

Phase I/II Study of Intratumoral Ad/Purine Nucleoside Phosphorylase (Gedeptin) With Fludarabine Phosphate in Patients With Recurrent Head and Neck Cancer

Functional Impact of Transoral Surgery and Risk-Based Adjuvant Therapy in Human Papillomavirus–Associated Oropharyngeal Cancer: Swallowing Outcomes From ECOG-ACRIN E3311 Ad/PNP (Gedeptin) is a ...
Seeking Alpha

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

SHELTON, Conn., May 29, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel ...

Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement

Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies ...